Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Development of a highly sensitive immunochemiluminometric assay for prostate-specific antigen

G G Klee1, C M Preissner, J E Oesterling

  • 1Department of Laboratory Medicine and Pathology, Mayo Clinic and Foundation, Rochester, Minnesota.

Urology
|July 1, 1994
PubMed
Summary

A new ultrasensitive assay accurately measures low prostate-specific antigen (PSA) levels, aiding early prostate cancer recurrence detection in patients post-prostatectomy.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Plasma islet amyloid polypeptide is not an effective tumor marker for pancreatic cancer even when protease inhibitors and rapid freezing of specimens are utilized.

Clinical chemistry·2001
Same author

Quantitation of 14-3-3 and neuron-specific enolase proteins in CSF in Creutzfeldt-Jakob disease.

Neurology·2001
Same author

Islet amyloid polypeptide is not a satisfactory marker for detecting pancreatic cancer.

Gastroenterology·2001
Same author

Neuropeptide Y, leptin, and cholecystokinin 8 in patients with advanced cancer and anorexia: a North Central Cancer Treatment Group exploratory investigation.

Cancer·2001
Same author

Development of a dual monoclonal antibody immunoassay for total human kallikrein 2.

Clinical chemistry·2001
Same author

Prolonged inhibition of presynaptic catecholamine synthesis with alpha-methyl-para-tyrosine attenuates the circadian rhythm of human TSH secretion.

Journal of the Society for Gynecologic Investigation·2001

Area of Science:

  • Biochemistry
  • Oncology
  • Assay Development

Background:

  • Prostate-specific antigen (PSA) is a key biomarker in prostate cancer management.
  • Monitoring PSA levels post-prostatectomy is crucial for detecting recurrence.
  • Existing assays may lack the sensitivity to detect very low PSA concentrations.

Purpose of the Study:

  • To develop and validate a highly sensitive assay for measuring low prostate-specific antigen (PSA) concentrations.
  • To provide a reliable tool for monitoring patients after radical prostatectomy.
  • To facilitate the early detection of prostate cancer recurrence.

Main Methods:

  • Development of a two-step, 90-minute chemiluminometric assay using monoclonal antibodies.
  • Utilized immobilized and acridinium ester-labeled antibodies for enhanced detection.

Related Experiment Videos

  • Standardized the assay against the Abbott IMx PSA Assay for comparability.

    • Main Results:

    • Achieved an analytic detection limit of 0.004 ng/mL and a biologic detection limit of 0.008 ng/mL.
    • Demonstrated high reproducibility with interassay coefficients of variation under 12% down to 0.02 ng/mL.
    • Classified as a "second generation" assay due to its performance at low concentrations.

    Conclusions:

    • The developed assay effectively measures very low PSA concentrations in plasma and a broad range in urine.
    • This ultrasensitive PSA assay is a valuable tool for evaluating clinical utility in prostate cancer management.
    • Enables enhanced monitoring for early detection of prostate cancer recurrence.